Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer
Chandra Prakash Belani, J. S. Lee, Mark A. Socinski et al. · Annals of Oncology · 2005
Cited by 145 works. doi:10.1093/annonc/mdi216
Authors
- Chandra Prakash Belani
- J. S. Lee
- Mark A. Socinski
- Francisco Robert
- David Michael Waterhouse
- Kendrith M. Rowland
- Rafat Ansari
- Rogério Lilenbaum
- Ronald B. Natale
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
- Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
- Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results